Finance
Mylan Teva EpiPen generic auto-injector market
- The FDA on Thursday approved Teva Pharmaceuticals’ generic version of the drug, dealing a blow to branded EpiPen-maker Mylan.
- Mylan saw an approximately 63% drop in EpiPen sales between 2017 and 2016, according to calculations made by Wells Fargo analyst David Maris.
- Analysts estimate that Teva estimate that Teva could control as much as a third of the approximate $750 million EpiPen market with its generic.
The EpiPen market is in for a major shakeup.
On Thursday, the FDA approved Teva Pharmaceuticals‘ generic version of the drug, dealing a blow to branded EpiPen-maker Mylan.
Depending on when Teva launches its generic alternative to the lifesaving allergy injection and what price it comes in at, it has a shot at picking up a big chunk of the epinephrine market as Mylan faces shortages and as parents look to stock up at the start of a new school year.
Mylan once controlled as much as 90% of the epinephrine market, though that percentage has declined in recent years to around 74%, according to a Wells Fargo estimate. An epinephrine auto-injector made by Impax Laboratories has picked up around 25% of the market, while Auvi-Q — which has a $4,500 for a two-pack list price — has about 2% of the market.
Raymond James analysts estimate that Teva could control as much as a third of the approximate $750 million epinephrine market, though it remains to be seen what drug companies Teva will take market share away from.
At its peak, Mylan made about $1 billion in sales a year from EpiPens. Then in 2016, the company came under scrutiny after the public realized that the list price of a two-pack of EpiPen had gone up from $93.88 to $608.61, an increase of more than 500% over a decade.
In response to that outcry, Mylan came out with a $300 generic version of the EpiPen which now makes up about half of the epinephrine market. That made an impact on EpiPen sales, and in 2017 Mylan said its branded sales fell by $655 million. Though the company didn’t break out its branded and generic sales for 2017, Wells Fargo analyst David Maris estimated it to be around $633 million in total.
While the outrage over the price of EpiPens died down, Mylan’s faced another challenge: shortages.
In May 2017, the FDA said that there was a shortage of EpiPens in the US, because of issues with the device’s manufacturer, Pfizer’s Meridian Medical Technologies. Mylan said on an earnings call last August that the device may not always be available, varying by pharmacy. Wells Fargo called up 53 pharmacies around the US and found that roughly half of them were out of both Mylan’s branded and generic EpiPens.
In part because of the lack of available EpiPens, prescription volume has been down compared to past years. “We believe there is pent-up demand,” Maris said. That could bode well for Teva, depending on when it launches its generic into the market.
See also:
-
Business7 days ago
Former top SpaceX exec Tom Ochinero sets up new VC firm, filings reveal
-
Business6 days ago
Consumer Financial Protection Bureau fines BloomTech for false claims
-
Business4 days ago
Langdock raises $3M with General Catalyst to help businesses avoid vendor lock-in with LLMs
-
Entertainment4 days ago
What Robert Durst did: Everything to know ahead of ‘The Jinx: Part 2’
-
Business6 days ago
Klarna credit card launches in the US as Swedish fintech grows its market presence
-
Entertainment3 days ago
This nova is on the verge of exploding. You could see it any day now.
-
Entertainment7 days ago
How to watch ‘The Sympathizer’: Release date and streaming deals
-
Entertainment6 days ago
How to set boundaries in the early stages of dating